# US 6,730,658 B1 · Stimulation of lymphatic growth with an FLT4 ligand

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 6,730,658 B1
- Document ID: US6730658B1
- Status: Granted
- Kind: B1
- Application number: 09/631,092
- Filed: 2000-08-02
- Granted: 2004-05-04
- Earliest claimed: 1994-11-14
- Assignees: Helsinki University Licensing, Ltd.; Ludwig Institute for Cancer Research
- Inventors: Kari Alitalo; Vladimir Joukov
- Web page: https://patentgrep.com/patent/US6730658B1

## CPC

- C07K 14/71: for growth factors; for growth regulators
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 9/14: Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
- A61P 17/00: Drugs for dermatological disorders
- A61P 17/02: for treating wounds, ulcers, burns, scars, keloids, or the like
- A61P 35/00: Antineoplastic agents
- C07K 14/475: Growth factors; Growth regulators
- C07K 14/52: Cytokines; Lymphokines; Interferons
- C07K 16/22: against growth factors {; against growth regulators}
- C07K 16/2863: {against receptors for growth factors, growth regulators}
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- A61K 2039/505: {comprising antibodies}
- C07K 2319/00: Fusion polypeptide
- C07K 2319/30: Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

Provided are methods of stimulating the growth of lymphatic endothelia using an Flt4 ligand.

## Claims

### Claim 1

A method of stimulating the growth of lymphatic endothelia, comprising steps of:
(a) identifying a patient in need of stimulation of the growth of lymphatic endothelia; and
(b) administering to the patient a polypeptide in an amount effective to stimulate the growth of lymphatic endothelial cells,
wherein the polypeptide comprises an amino acid sequence encoded by a polynucleotide that hybridizes to the non-coding strand complementary to the cDNA sequence of SEQ ID NO: 32 under the following hybridization conditions:
hybridization at 42° C. in a hybridization solution comprising 50% formamide, 5×SSC, 20 mM Na.PO4, pH 6.8 and washing in a wash solution comprising 0.2×SSC at 55° C., and
wherein the polypeptide binds and stimulates phosphorylation of Flt4 receptor tyrosine kinase.

### Claim 2

A method of stimulating the growth of lymphatic endothelia, comprising steps of:
(a) identifying a patient in need of stimulation of the growth of lymphatic endothelia; and
(b) administering to the patient a polypeptide in an amount effective to stimulate the growth of lymphatic endothelial cells,
wherein the polypeptide binds and stimulates phosphorylation of Flt4 receptor tyrosine kinase and comprises an amino acid sequence encoded by the cDNA contained in ATCC Deposit No. 97231 or a fragment thereof that binds and stimulates phosphorylation of Flt4 receptor tyrosine kinase.

### Claim 3

A method of stimulating the growth of lymphatic endothelia, comprising steps of:
(a) identifying a patient in need of stimulation of the growth of lymphatic endothelia; and
(b) administering to the patient a polypeptide, in an amount effective to stimulate the growth of lymphatic endothelial cells,
wherein the polypeptide binds and stimulates phosphorylation of Flt4 receptor tyrosine kinase and comprises the amino acid sequence in SEQ ID NO: 33 or a fragment thereof that binds and stimulates phosphorylation of Flt4 receptor tyrosine kinase.

### Claim 4 (depends on 3)

A method according to claim 3, wherein the polypeptide comprises amino acids 113-213 of SEQ ID NO: 33.

### Claim 5 (depends on 4)

A method according to claim 4, wherein the polypeptide lacks amino acids 227 to 419 of SEQ ID NO: 33.

### Claim 6 (depends on 5)

A method according to claim 5, wherein the polypeptide lacks amino acids 1 to 102 of SEQ ID NO: 33.

### Claim 7 (depends on 1, 2, 3, 4, 5, 6)

A method according to any one of claims 1-6, wherein the identifying step comprises selecting a patient having lymphatic vessel loss or damage due to surgical intervention,
wherein the polypeptide binds and stimulates phosphorylation of Flt4 expressed in endothelial cells, and
wherein the polypeptide is administered in an amount effective to stimulate growth of lymphatic endothelia.

### Claim 8 (depends on 7)

A method according to claim 7, wherein the polypeptide is administered in an amount effective to stimulate regrowth of lymphatic vessels.

### Claim 9 (depends on 1, 2, 3, 4, 5, 6)

A method according to any one of claims 1-6, wherein the identifying step comprises identifying a patient having or at risk for developing edema,
wherein the polypeptide binds and stimulates phosphorylation of Flt4 expressed in endothelial cells, and
wherein the polypeptide is administered in an amount effective to stimulate growth of lymphatic endothelia.

### Claim 10 (depends on 1, 2, 3, 4, 5, 6)

A method according to any one of claims 1-6, wherein the identifying step comprises identifying a patient having lymphatic vessel aplasia,
wherein the polypeptide binds and stimulates phosphorylation of Flt4 expressed in endothelial cells, and
wherein the polypeptide is administered in an amount effective to stimulate growth of lymphatic endothelia.

### Claim 11 (depends on 1, 2, 3, 4, 5, 6)

A method according to any one of claims 1-6, wherein the identifying step comprises selecting an organ transplant patient,
wherein the polypeptide binds and stimulates phosphorylation of Flt4 expressed in endothelial cells, and
wherein the polypeptide is administered in an amount effective to stimulate growth of lymphatic endothelia.

### Claim 12 (depends on 1, 2, 3, 4, 5, 6)

A method according to any one of claims 1-6, wherein the identifying step comprises identifying a patient having reduced lymphatic vessel function due to lymphatic vessel blockage,
wherein the polypeptide binds and stimulates phosphorylation of Flt4 expressed in endothelial cells, and
wherein the polypeptide is administered in an amount effective to stimulate growth of lymphatic endothelia.

### Claim 13 (depends on 1, 2, 3, 4, 5, 6)

A method according to any one of claims 1-6, wherein the identifying step comprises identifying a patient having lymphatic vessel occlusion,
wherein the polypeptide binds and stimulates phosphorylation of Flt4 expressed in endothelial cells, and
wherein the polypeptide is administered in an amount effective to stimulate growth of lymphatic endothelia.

### Claim 14 (depends on 1, 2, 3, 4, 5, 6)

A method according to any one of claims 1-6, wherein the identifying step comprises identifying a patient having elephantiasis,
wherein the polypeptide binds and stimulates phosphorylation of Flt4 expressed in endothelial cells, and
wherein the polypeptide is administered in an amount effective to stimulate growth of lymphatic endothelia.

### Claim 15 (depends on 1, 2, 3, 4, 5, 6)

A method according to any one of claims 1-6, wherein the administering step comprises administering a composition that comprises the polypeptide and a diluent, adjuvant, excipient, or carrier.
